VIVEX Biologics

What VIVEX Biologics does

VIVEX Biologics, Inc. is a privately held regenerative medicine company founded in 2012 and headquartered in Miami, Florida, with a secondary corporate office in Atlanta, Georgia. The company processes, stores, and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) under FDA registration and AATB accreditation, supported by a wholly-owned tissue-banking subsidiary, Legacy Donor Services Foundation (DSF). Its portfolio is organized into three therapy areas: Ortho & Fusion Therapies, Wound Care & Amnion Therapies, and Interventional Pain Therapies, serving spine/orthopedic surgeons, wound care specialists, and interventional pain physicians.

VIVEX's product portfolio centers on allograft processing under its proprietary Integrity Processing™ methodology, a trade-secret workflow that avoids harsh cleaning agents to preserve native tissue characteristics. Flagship products include VIA Form+™ (a viable bone scaffold with mineralized cancellous bone plus demineralized cortical fibers), VIA Mend™ (a bioactive strip combining carbonate apatite, 45S5 bioactive glass, and Type I collagen), the VIA DBM family (putty, sponge, strip, fibers), and amniotic allografts under the CYGNUS®, VIAGENEX® (Matrix, Max, Solo, Dual), VIA Matrix™, and MIAMNION brands. The Cygnus and VIAGENEX product lines preserve up to 600-700+ signaling proteins, and VIA Form+ retains viable endogenous bone cells to support osteogenic healing. Clinical evidence includes peer-reviewed publications reporting 100% radiographic fusion success at six months and zero adverse events at three years for VIA Form+ in lumbar interbody fusion (n=14).

The company operates a sales-led go-to-market combining direct sales to hospitals and medical professionals with an Amnion & Wound Care Distribution Network of approved third-party distributors and a dedicated distributor portal. Pricing is quote-based and not publicly disclosed. Revenue is generated through one-time product sales across the three therapy areas, with end customers being healthcare providers rather than consumers. VIVEX does not disclose revenue, has no visible funding rounds, and is privately held with no stated parent company, although its operating complexity — multi-jurisdictional licensing, subsidiary tissue banking operations, broad SKU portfolio, and clinical evidence investment — is consistent with a commercial-stage regenerative medicine business rather than a pre-revenue startup.

Name

VIVEX Biologics

Legal name

VIVEX Biologics, Inc.

Website

https://vivex.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

VIVEX Biologics is a privately held Miami-based regenerative medicine company that processes and distributes allograft products — bone grafts, amniotic membrane grafts, and disc tissue therapies — to hospitals and medical professionals for spine, orthopedic, wound care, and interventional pain applications under proprietary Integrity Processing™.

Ownership category

akta.pro rank

Product category

Orthobiologics

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Allograft tissue products
• Regenerative medicine solutions
• Bone graft substitutes
• Amniotic membrane allografts
• Wound care therapies

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Allograft Product Sales: VIVEX processes, stores, and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) and distributes medical devices to hospitals, medical professionals, and approved distributors. Revenue is generated through product sales across three therapy areas: Ortho & Fusion Therapies, Wound Care & Amnion Therapies, and Interventional Pain Therapies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

VIVEX Biologics processes, stores, and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) allografts for hospitals, medical professionals, and approved distributors. Its portfolio spans bone allografts (VIA Form+, VIA DBM family, VIA Graft, VIA Fill, VIA Mend), amniotic membrane allografts (Cygnus Matrix/Dual, VIAGENEX family, VIA Matrix, MIAMNION), and allogeneic disc tissue therapies (VIA Disc NP) across orthopedics/fusion, wound care, and interventional pain. Manufacturing uses the proprietary Integrity Processing™ methodology under FDA registration, AATB accreditation, and multi-state tissue-bank licensing.

Product overview

VIVEX Biologics develops and delivers innovative allografts for regenerative medicine. The portfolio includes bone allografts (VIA Form+, VIA DBM family products, VIA Graft, VIA Fill, VIA Mend products), amniotic membrane products (Cygnus Matrix, Cygnus Dual, VIAGENEX family, VIA Matrix, MIAMNION), and disc tissue therapies (VIA Disc NP). Products are organized by therapy area: Ortho & Fusion Therapies, Wound Care & Amnion Therapies, and Interventional Pain Therapies. The company uses proprietary Integrity Processing methodology to preserve tissue properties while maintaining safety standards compliant with FDA and AATB requirements.

Differentiator

Problem solved

Functional benefit

Brands

• CYGNUS: Amnion-based skin substitutes including Cygnus Matrix and Cygnus Dual for wound care
• VIA
• VIA DBM
• VIA Form+
• VIA Disc NP
• VIA Matrix
• VIAGENEX
• VIA Mend
• VIA Fill
• VIAGENEX
• VIA Graft
• MIAMNION

Products and services

• VIA Form+ Viable bone scaffold composed of mineralized cancellous bone with demineralized cortical fibers, containing viable endogenous bone cells for osteogenic healing. Used in spine, upper extremity, foot and ankle, oral and maxillofacial, and orthopedic oncology procedures.
• VIA Graft Viable allogeneic bone matrices for orthopedic and fusion applications, supporting bone healing and fusion procedures.
• VIA DBM Putty Demineralized bone matrix putty for orthopedic and fusion applications.
• VIA DBM Plus Demineralized bone matrix paste with chips for orthopedic and fusion applications.
• VIA DBM Sponge Demineralized bone matrix cancellous sponge for orthopedic and fusion applications.
• VIA DBM Strip Demineralized bone matrix cancellous strip for orthopedic and fusion applications.
• VIA Fill Demineralized bone matrix fibers for orthopedic and fusion applications.
• VIA Mend Putty Moldable bone graft putty substitute that can be molded to fit bone defects for bony void filling applications.
• VIA Mend Strips Moldable, flexible, absorbent bone graft strips that resist migration upon irrigation for bony void or gap treatment. Composed of 50% carbonate apatite anorganic bone mineral, 30% 45S5 bioactive glass, and 20% Type I collagen.
• VIA Disc NP Allogeneic disc tissue therapy for supplementing degenerated intervertebral discs in interventional pain procedures.
• Cygnus Matrix Amnion-based skin substitute for wound care applications including diabetic foot ulcers and venous leg ulcers. Performs equal or better than Medicare-covered alternatives and is associated with reduced therapy duration and lower amputation rates.
• Cygnus Dual Dual-layer amnion-based skin substitute for wound care applications, offering enhanced structural integrity for chronic and acute wound treatment.
• VIAGENEX Matrix Flexible, multi-layer amniotic allograft maintaining amnion, intermediate/spongy layer, and chorion layers of the amniotic sac for improved handling, increased workability, and up to 600+ retained signaling proteins.
• VIAGENEX Max Maximum natural thickness allograft derived from the umbilical cord membrane that can be sutured; preserves the rich supply of extracellular matrix, growth factors, and cytokines.
• VIAGENEX Solo Traditional single-layer amniotic membrane graft for wound care and surgical applications.
• VIAGENEX Dual Dual-layered amniotic graft for wound care and surgical applications.
• VIA Matrix Multi-layer amniotic tissue grafts used as a tissue barrier or wound covering to help protect damaged tissue in wound care, venous leg ulcers, dermatology, and pressure wounds; preserves up to 700+ signaling proteins without delamination.

Quantifiable outcome

• 100% radiographic fusion success within 6 months in lumbar interbody fusion patients (n=14)
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Distribution PartnerscoreChannel Partner/ Reseller/ DistributorVIVEX Biologics has established a distribution partner network for their Amnion & Wound Care products. The company is actively expanding this network and offers a distributor portal for partner management. Partners receive access to the full portfolio of amniotic allografts and wound care products.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Arthrex: Arthrex is a large orthopedic device company with an orthobiologics portfolio including allograft options for sports medicine and foot/ankle — comparable to VIVEX's VIA Form+, VIA Mend, and VIA Graft products as a broader incumbent serving similar orthopedic surgeons.
• Globus Medical: Globus Medical (now merged with NuVasive) is a major spine company with an orthobiologics portfolio addressing spinal fusion — comparable to VIVEX's VIA Form+ and VIA Graft spine allografts as a broader spine-focused incumbent with adjacent biologic offerings.
• Integra LifeSciences: Integra LifeSciences is a diversified medical device company with regenerative tissue technologies (Integra Dermal Regeneration Template) and orthobiologic offerings — comparable to VIVEX as a broader incumbent with overlapping wound care and orthobiologic capabilities, though operating across many more product categories.
• Stryker (Orthobiologics / Wright Medical): Stryker (including its Wright Medical acquisition) sells bone graft substitutes, biologics, and orthobiologic products to orthopedic surgeons — comparable to VIVEX's bone void filler portfolio (VIA Form+, VIA Mend, DBM family) as a large, diversified incumbent in the same end market.

Direct peers

• Organogenesis: Organogenesis manufactures advanced wound care products including skin substitutes (Apligraf, Dermagraft) — directly comparable to VIVEX's Cygnus amniotic skin substitutes for diabetic foot ulcers, venous leg ulcers, and chronic wound healing.
• MiMedx: MiMedx develops and distributes placental tissue allografts (EpiFix, AmnioFix) for wound care and musculoskeletal applications — directly comparable to VIVEX's Cygnus, VIAGENEX, and VIA Matrix amniotic membrane portfolio in both product format and target customers (wound care clinics, orthopedic surgeons).
• LifeNet Health: LifeNet Health is a non-profit tissue banking and allograft processor with broad orthopedic, spine, and wound care product lines — directly comparable to VIVEX across HCT/P processing, AATB-accredited operations, and allograft distribution to hospitals.
• MTF Biologics: MTF Biologics is one of the largest U.S. tissue banks, processing and distributing allografts for orthopedics, spine, and wound care — directly comparable to VIVEX's tissue banking operations, Integrity Processing methodology, and orthopedic/wound allograft portfolio.
• AlloSource: AlloSource is an AATB-accredited tissue bank producing allografts for spine, orthopedics, sports medicine, and wound care — directly comparable to VIVEX's product breadth across bone grafts, amniotic membranes, and soft tissue allografts.

Emerging players

• Surgenex: Surgenex is a smaller emerging competitor in amniotic membrane and tissue allograft products targeting orthopedics and wound care — comparable to VIVEX as a niche emerging player with overlapping amniotic allograft product formats and similar end customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/VIVEXbiologics
• LinkedInlinkedin.com/company/vivex-biologics

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VIVEX Biologics